General Notes
This product (Catalog No. DPABH-29252) is a rabbit-derived polyclonal antibody raised against human ATP1A3, targeting the amino acid region 1–65 of the protein. This antibody exhibits cross-reactivity with Human ATP1A3 from mouse and rat. It has been affinity purified by Protein A. ATP1A3 participates in the catalyticing hydrolysis of ATP and the exchanging of sodium and potassium ions across plasma membrane. The catalyticing activity mode is ATP + H2O + Na+(In) + K+(Out) = ADP + phosphate + Na+(Out) + K+(In). It has been published that the neurologic disorders rapid-onset dystonia-parkionsonism (RDP), alternating hemiplegia of childhood (ACH) and CAPOS syndrome (cerebellar ataxia, areflexia, pes cavus, optic atrophy and sensorineural hearing loss) are all related with the mutation of ATP1A3. There are other reports suggest that early life epilepsy and episodic apnea revealing are potentially associated with the mutation of ATP1A3 as a result of impairment of Na/K homeostasis.
DPABH-29252 is suitable for use in Western blot (WB) (1:2,000–1:16,000), IP (0.5-4.0 μg for 1.0-3.0 mg of total protein lysate), IHC (1:50–1:500), IF-P (1:50–1:500) applications.
DPABH-29252 is supplied as a liquid formulation in PBS with 0.02% sodium azide and 50% glycerol, pH 7.3. For long-term storage, keep at −20 °C. For short-term use, store at 2–8 °C. Avoid repeated freeze–thaw cycles to maintain antibody integrity and performance.
COA
Publication 
Loading ......
